Search
Close this search box.

Another Biosimilar to Avastin – Avzivi

……..catching up on FDA Approvals

The FDA recently approved a new infused therapy, Avzivi (bevacizumab-tnjn) from Bio-Thera Solutions, as a biosimilar to AVASTIN (bevacizumab). It did not receive an interchangeable designation.

Avzivi is indicated for the treatment of (refer to prescribing information for full indication):

  • Metastatic colorectal cancer, in combination 
  • Metastatic colorectal cancer, in combination 
  • Non-squamous non-small cell lung cancer, in combination 
  • Recurrent glioblastoma in adults
  • Metastatic renal cell carcinoma in combination 
  • Cervical cancer, in combination 
  • Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination.

CLICK HERE to access prescribing information

Four biosimilar versions of Avastin were previously approved: 

  • Mvasi (bevacizumab-awwb), 
  • Zirabev (bevacizumab-bvzr), 
  • Alymsys (bevacizumab-maly), and 
  • Vegzelma (bevacizumab-adcd).

——————————————————————————————–

FDA Approves Bio-Thera Solutions’ Avzivi (bevacizumab-tnjn), a biosimilar referencing Avastin

  • Avzivi (BAT1706) is Bio-Thera Solutions’ second FDA approved product in the United States
  • Avzivi® is the second biosimilar researched, developed, and manufactured by a Chinese pharmaceutical company to receive FDA approval in the United States

CLICK HERE to read the full press release

Share:

Read More

CGT Driving New Programs at WAGS

Our last few Reports focused on approvals and developments in the Cell and Gene Therapy (CGT) categories. A recent press release from a major national pharmacy

CGT

CGT…… What’s in Your Future?

Today we are pleased to offer a review of an article from which just about anyone working in the specialty pharmacy segment might learn something…. or

Send Us A Message

This website uses cookies to ensure you get the best experience on our website.